Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Nexia Biotechnologies Inc Company Profile

03:33 EDT 21st April 2014 | BioPortfolio

Until recently Nexia developed and manufactured complex recombinant proteins in the milk of transgenic goats for medical and industrial applications. The Company's two lead programs were Protexia and BioSteelR.On March 7, 2005, Nexia's, shareholders approved the sale of substantially all its operations and assets related to ProtexiaR to PharmAthene (www.pharmathene.com), a privately held biotechnology company focused on the development of biodefense therapeutics, based in Annapolis, Maryland, USA.

Location

P.O. BOX 187Branch Jean-Talon
Montreal
Quebec
H1S 2Z2
Canada

Contact

Phone: 514.586.3942
Fax: 514.371.7880
Email: investors@nexiabiotech.com


News Articles [81 Associated News Articles listed on BioPortfolio]

immatics biotechnologies GmbH - Product Pipeline Review - 2014

immatics biotechnologies GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘immatics biotechnologies GmbH - Product Pipeline Review - 2014’, provides an overview of the imma...

Adaptive Biotechnologies secures $105M from private investor

Adaptive Biotechnologies said it has raised $105 million in private funding from Viking Global Investors, bringing its total  -More- 

Adaptive Biotechnologies raises $5mm through Series C; later adds $5mm more

Adaptive Biotechnologies Corp. (formerly Adaptive TCR; immune system profiling for diagnostics and drug development) raised $5mm from three investors in its Series C round.

Roth starts Lion Biotechnologies at buy

Roth Capital Partners has initiated coverage of Lion Biotechnologies (OTC:LBIO) with a “buy” rating and $10 price target. The stock closed at $6 on Wednesday. Lion, formerly Genesis Biopharma, is...

Stockboard Media Inc.: Custom Stock Reports and Mobile Notifications on Stellar Biotechnologies, Inc.

Richmond, British Columbia--(Newsfile Corp. - January 7, 2014) - Custom email stock reports and mobile news alert service for Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSXV: KLH) are now availa...

Lion Biotechnologies to Present at the LD MICRO Conference on December 3

Lion Biotechnologies, Inc. (OTC Markets: LBIO) announced that Chief Financial Officer Michael Handelman will present at the 6th Annual LD MICRO Conference on Tuesday, December 3,...

Roth ups Lion Biotechnologies target to $20

Roth Capital Partners has raised its price target for “buy-rated” Lion Biotechnologies (OTC:LBIO) to $20 from $15, after Dr. Steven Rosenberg of the NCI presented Phase 2 data at the American Asso...

CytoVale, Pareto Biotechnologies receive grants from Breakout Labs

Breakout Labs, a program of the Thiel Foundation, has announced its support of two new early-stage companies leveraging cell-based technologies: CytoVale and Pareto Biotechnologies. The new grants bri...

Drugs and Medications [0 Results]

None

PubMed Articles [10 Associated PubMed Articles listed on BioPortfolio]

Biotechnologies in developing countries: present and future.

Enrichment of Y-Chromosome-Bearing Bull Spermatozoa by Swim-up Through a Column.

With the advancement of assisted reproductive biotechnologies, preselecting the sex of offspring has become an important goal for cattle and other livestock breeding as well as for research. The aim o...

A single vector-based strategy for marker-less gene replacement in Synechocystis sp. PCC 6803.

The cyanobacterium Synechocystis sp. PCC 6803 is widely used for research on photosynthesis and circadian rhythms, and also finds application in sustainable biotechnologies. Synechocystis is naturally...

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.

Breast cancer includes a body of molecularly distinct subgroups, characterized by different presentation, prognosis, and sensitivity to treatments. Significant advances in our understanding of the com...

Dermic diffusion and stratum corneum: A state of the art review of mathematical models.

Transdermal biotechnologies are an ever increasing field of interest, due to the medical and pharmaceutical applications that they underlie. There are several mathematical models at use that permit a...

Clinical Trials [0 Results]

None

Companies [95 Associated Companies listed on BioPortfolio]

Nexia Biotechnologies Incorporated

Nexia Biotechnologies is one of the world's largest producers of authentic recombinant spider silk, and a leading North American animal transgenic company. Nexia manufactures biomaterials and therapeu...

Nexia Biotechnologies Inc

Until recently Nexia developed and manufactured complex recombinant proteins in the milk of transgenic goats for medical and industrial applications. The Company's two lead programs were Protexia and...

Nexia Holdings, Inc.

Genemed Biotechnologies Incorporated

Genemed Biotechnologies Inc. provides high quality contract manufacturing services for a wide variety of research and diagnostic products including native or recombinant proteins and nucleotides

Epeius Biotechnologies Corp.

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology pro...

More Information about "Nexia Biotechnologies Inc" on BioPortfolio

We have published hundreds of Nexia Biotechnologies Inc news stories on BioPortfolio along with dozens of Nexia Biotechnologies Inc Clinical Trials and PubMed Articles about Nexia Biotechnologies Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nexia Biotechnologies Inc Companies in our database. You can also find out about relevant Nexia Biotechnologies Inc Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement